|
CA3089742A1
|
|
Cholestyramine formulations and methods of use
|
|
CA2976819A1
|
|
Benzimidazole compounds as kinase inhibitors
|
|
CA2965813A1
|
|
Spirocyclic containing compounds and pharmaceutical uses thereof
|
|
CA2946982A1
|
|
Nystatin nanosuspension formulation using high pressure homogenisation
|
|
CA2939286A1
|
|
Spirocyclic containing compounds and pharmaceutical uses thereof
|
|
TW201712017A
|
|
Inhibitors of the TEC kinase enzyme family
|
|
EP3337805A1
|
|
Inhibitors of the tec kinase enzyme family
|
|
CA2916970A1
|
|
A smac mimetic compound for use in the treatment of proliferative diseases
|
|
CA2906137A1
|
|
Novel protein kinase inhibitors
|
|
CA2904270A1
|
|
Protein kinase inhibitors
|
|
CA2845443A1
|
|
Orally disintegrating tablet of nabilone and method of manufacturing
|
|
CA2834528A1
|
|
Protein kinase inhibitors
|
|
CA2833867A1
|
|
Protein kinase inhibitors
|
|
CA2833701A1
|
|
Protein kinase inhibitors
|
|
CA2817728A1
|
|
Abuse deterrent immediate release formulation
|
|
US2015191473A1
|
|
Selective inhibitors of Tec and Src protein kinase families
|
|
CA2813299A1
|
|
Protein kinase inhibitors
|
|
CA2791206A1
|
|
Abuse deterrent pharmaceutical formulation
|
|
CA2787472A1
|
|
Protein kinase inhibitors
|
|
CA2782774A1
|
|
Protein kinase inhibitors
|
